![New Cancer Diagnostic Tests Stand Out](https://www.g2intelligence.com/wp-content/uploads/2023/01/Jan24-2023.News_.DxAnnouncements-iStock-1800x1250-1-1080x675.jpg)
New Cancer Diagnostic Tests Stand Out
Key Dx announcements last week involved companion diagnostics, liquid biopsy assays, and an RUO leukemia test.
Key Dx announcements last week involved companion diagnostics, liquid biopsy assays, and an RUO leukemia test.
Get an overview of trending areas of enforcement and steps labs and pathology practices can consider to protect their businesses.
The flexibility of compact, mobile, photoacoustic imaging equipment on wheels is helping to advance groundbreaking medical research, diagnostics, and treatment.
Even though PAMA has slashed reimbursement rates for many tests, overall Medicare Part B spending on lab tests continues to increase.
At the end of 2022, the agency sent a new warning letter to Empowered for unauthorized distribution of COVID-19 test kits.
Case is a recent example of the trend toward Medicare schemes involving telehealth, cancer genetic testing, and kickbacks.
While the federal spending bill passed at the end of 2022 will have a large impact on clinical labs, it doesn’t include LDTs reform.
Legislation offering permanent relief from both PAMA price cuts and reporting didn’t make it into the federal spending bill passed Dec. 23.
The new practice guideline also recommends NIPS to screen for fetal sex chromosome aneuploidy.
In last week’s key cases, those involved in UDT fraud schemes face the music, and a doctor is convicted of stealing COVID relief money.